

# Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	ADARx Pharmaceuticals, Inc.
<b>Enrollment</b>	45 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Mean eGFR greater than or equal to 30 mL/min/1.73m<sup>2</sup>
- Clinical evidence of active kidney disease
- Treated with supportive care including an ACE inhibitor or ARB if applicable
- Willing to receive required vaccinations
- Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy

### Exclusion (8)

- Hereditary or acquired complement deficiency
- Kidney transplant or renal replacement therapy
- History of solid organ transplant
- Other kidney disease
- History of recurrent invasive infections

... and 3 more (see full listing online)

## Locations (12 total)

---

ADARx Clinical Site, Shreveport, Louisiana, United States  
ADARx Clinical Site, Shelby, Michigan, United States  
ADARx Clinical Site, Dakota Dunes, South Dakota, United States  
... and 9 more locations